- Harvard & MIT (MD, magna cum laude);
PhD (laser physics) - Over 25,000 LASIK and cataract procedures (including on over 3,000 doctors)
- Introduced bladeless all-laser LASIK to the state
- Implanted the state's first new premium lens for cataract surgery
- Was the first surgeon in the US to perform a new Intacs surgery to treat severe keratoconus
- Helped patients from 40 states and 55 countries
- International referral center for cataract surgery and treating LASIK complications
- Read Dr. Wang's book: LASIK Vision Correction
 |
 |
 |
Why did you decide to have LASIK? Why did you choose Dr. Wang? How has your life changed since your LASIK procedure? What is your advice for people considering LASIK? - Click to see more
 |
Corneal Intrastromal Gatifloxacin Crystal Deposits After Penetrating Keratoplasty
Eye & Contact Lens: Science & Clinical Practice: July 2004 - Volume 30 - Issue 3 - pp 169-172
Awwad, Shady T. M.D; Haddad, Walid M.D; Wang, Ming X. M.D., Ph.D; Parmar, Dipak M.B.B.S., B.Sc.(Hons.), F.R.C.Ophth; Conger, Darrel C.R.A; Cavanagh, H Dwight M.D., Ph.D
Abstract
Background. An 85-year-old man developed faint crystallike white precipitates in the mid peripheral stroma of his left cornea 3 weeks after undergoing penetrating keratoplasty. The patient had been initially treated with 1% prednisolone acetate ophthalmic suspension and 0.3% gatifloxacin eyedrops to his left eye from the first day postoperatively. Three weeks later, the precipitates were more numerous, larger, and diffuse in distribution. Gatifloxacin was discontinued and substituted with a neomycin-polymixin B-dexamethasone ophthalmic ointment.
Methods. A detailed history, physical examination, laboratory workup, and tandem scanning confocal microscopy were performed.
Results. Tandem scanning corneal confocal microscopy confirmed the presence of crystals in the cornea.
Conclusions. Gatifloxacin, a fourth-generation fluoroquinolone, can cause intrastromal macroscopic crystalline deposits through a compromised corneal epithelium, similar to what has been described for ciprofloxacin, a second-generation fluoroquinolone.
© 2004 Lippincott Williams & Wilkins, Inc.
